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Impact of the Affordable Care Act on Early Stage Cervical Cancer Diagnoses in 
Pennsylvania: An Interrupted Time Series Analysis 
Jennie Elizabeth Duquette, M.S. 
 





Significant advances in cervical cancer screening have led to improved survival rates and 
reduced cancer burden in the United States but disparities remain. Race, socioeconomic and 
insurance status and region strongly influence cervical cancer outcomes. The Affordable Care Act 
(ACA) included multiple provisions that aimed to expand access to coverage and cancer screening 
and care. The purpose of this study was to investigate the impact of ACA, following Medicaid 
expansion, on early stage cervical cancer diagnoses for women in Pennsylvania, with a focus on 
minority women and rurally located women. The study utilized data from the Pennsylvania Cancer 
Registry, a statewide data system responsible for collecting information on all new cancer cases 
diagnosed in Pennsylvania, to identify cervical cancer cases in Pennsylvania from 2010 through 
2016. The effect of Medicaid expansion in Pennsylvania through implementation of the ACA was 
assessed on cancer stage at diagnosis using a retrospective natural experiment design and 
interrupted time series analysis. Multiple logistic regression models utilizing the interrupted time 
series analysis framework were estimated to assess the relationships between the implementation 
of the ACA, patient characteristics and the likelihood of an early stage cervical cancer diagnosis. 
A total of 2,052 cervical cancer cases in women aged 26 to 64 years were included in analysis over 
the study period between 2010 and 2016. Average age of the sample was 46 years (SD = 10.24). 
Most women were white (79.74%) and non-Hispanic (90.99%) and were privately insured 
(52.13%). The study did not find a significant effect of ACA implementation on early stage 
 v 
cervical cancer diagnoses across Pennsylvania, both when examining the full sample and when 
stratifying to examine effects for specific subpopulations, but results do highlight interesting trends 
in patterns of cervical cancer diagnosis between 2010 and 2016 motivating further research.  
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1.0 Background and Significance 
The American Cancer Society estimates that almost 15,000 new cases of invasive cervical 
cancer will be diagnosed in the United States in 2021 and that over 4,000 of those women may die 
from the disease. Cervical cancer was previously the leading cause of cancer death for American 
women. However, with significant advances in screening, including the widespread use of the 
Papanicolaou (Pap) test and the HPV test, mortality rates have significantly declined over the last 
40 years (American Cancer Society, 2021). Despite these improvements, disparities in cervical 
cancer incidence and mortality remain. Race, socioeconomic status, and region strongly influence 
cervical cancer outcomes. For example, the five-year survival rate for Black women is 58% 
compared to 71% for white women (American Cancer Society, 2021). Cervical cancer incidence 
and mortality rates are also higher in rural and nonmetropolitan areas than in metropolitan areas 
(Yu, Sabatino, & White, 2019).  
The Appalachian region, in particular, experiences higher incidence and mortality due to 
cervical cancer when compared with other regions of the United States (Yao, 2016). This 420-
county region extends from New York down through to northern Mississippi. Around 42% of the 
Appalachian region is considered rural, compared with only 20% of the U.S. population 
(Appalachian Regional Commission, 2020). In addition, systemic factors such as a lack of 
comprehensive healthcare facilities and providers, contribute to the observed disparities in cervical 
cancer seen in the region. These systemic challenges are often exacerbated by socioeconomic 
factors such as high rates of poverty and low levels of health literacy and education which often 
result in poorer observed health behaviors and infrequent contact with health care providers 
(Paskett et al., 2020).  
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Pennsylvania presents a useful case through which to examine differences in access to 
cervical cancer screening care and outcomes given the geographically diverse population and 
number of counties designated as part of the Appalachian region. It is also important to 
acknowledge the diverse experiences of individuals who reside in the Appalachian region of the 
United States. The region encompasses a broad range of populations and communities and public 
health challenges cannot be generalized across the whole of the region. This paper aims to shed 
light on the relationships between health care access and women’s health outcomes in one state of 
the region to inform future research directions and public health solutions.  
1.1 Literature Review 
Review of previous literature demonstrates that women who are uninsured are less likely 
to utilize cancer screening services and are more likely to present with a later stage cancer at 
diagnosis and to have poorer survival outcomes (Chen et al., 2012; Sabik et al., 2015; Churilla et 
al., 2016). Early stage diagnosis of cervical cancer is associated with improved survival rates, less 
aggressive treatments and overall improved quality of life (American Cancer Society, 2021). Rural 
women, in particular, are more likely to fall under the category of uninsured (Cheeseman Day, 
2019). The first section of this review will discuss early policy reform in the 1990s and early 2000s 
which established the foundations for preventative women’s health care while the second section 
highlights modern reforms in the context of the Affordable Care Act (ACA).  
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1.1.1 Early Reform in Cervical Cancer Care 
In 1990, Congress enacted the National Breast and Cervical Cancer Early Detection 
Program (NBCCEDP) as an amendment to the Public Health Service to improve access to 
screening. Despite advances in screening in both breast and cervical cancer beginning in the mid 
20th century, low income and minority women were less likely to be screened for both types of 
cancers four decades later (Hardy et al., 1996). Among US women aged 18 years and older, 75% 
had received Pap testing within the preceding 3 years to screen for cervical cancer. However, poor 
and uninsured women were much less likely to have received a Pap test (Lee et al., 2014). Congress 
established the program to address these significant disparities. The program provides grants to 
states to fund breast and cervical cancer screening, support services, case-management services 
(added by amendments enacted in 1998), and other services and activities aimed at developing 
greater capacity to serve at-risk populations. Since its 1991 implementation, the NBCCEDP has 
provided service for nearly 10 million breast and cervical cancer screening exams to almost four 
million women, with diagnoses of more than 52,000 breast cancers, 2,800 invasive cervical 
cancers, and nearly 137,000 premalignant cervical lesions (Rosenbaum, 2012). Despite the 
program’s significant accomplishments in expanding access to screenings to women across the 
nation, the program lacked provisions to finance the treatment and follow up of abnormal screening 
results. Lack of follow up care and treatment left uninsured women especially vulnerable with few 
resources to rely on after receiving abnormal results. Moreover, due to the underwriting policies 
of the individual markets, independently purchasing a private policy would have been impossible 
for an uninsured woman with abnormal test results. In 2000, Congress enacted the Breast and 
Cervical Cancer Prevention and Treatment Act (BCCPTA) to address the gaps in coverage for 
treatment. 
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The BCCPTA established a state Medicaid eligibility option to cover uninsured women, 
regardless of income or assets, whose screenings through NBCCEDP revealed abnormal results. 
All states have adopted the expansion option, although variations exist in program design, 
eligibility and administration (Rosenbaum, 2012). Women were only able to enroll in the program 
after abnormal results had been found, often leading to delays in treatment. Lantz et al. (2009) uses 
a longitudinal time series design using data from 1995 through 2005 to evaluate the impact that 
the Medicaid expansions enacted through the BCCPTA may have had on time to diagnosis and 
time to treatment for women with abnormal breast and cervical cancer screening results. The 
authors found that the Act did have some positive impacts including a 12.8% decrease in the 
average number of days to definitive cervical diagnosis for white women. However, results also 
showed that the average time between diagnosis of cervical dysplasia or cancer and the initiation 
of treatment for Black and Hispanic women significantly increased after implementation of the 
policy. The authors discuss that these results may be explained by racial/ethnic disparities that 
exist in regard to access to gynecologists and other clinicians who treat cervical conditions and 
accept Medicaid patients. It is important to consider modern reforms to cervical cancer care policy 
to understand the ways modern reform intended to address these shortcomings of early programs 
and to highlight areas that may still need further adjustment and improvement.  
1.1.2 Modern Reform in Cervical Cancer Care: the Affordable Care Act  
The Affordable Care Act (ACA) included multiple provisions that aimed to expand access 
to coverage and cancer screening and care. Literature at the intersection of health care reform 
through the ACA and the cervical cancer care continuum has focused on three main provisions of 
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the ACA: the dependent coverage mandate, Medicaid expansion and the elimination of cost 
sharing for preventative services for privately insured individuals.  
Early data following implementation of the ACA from the National Cancer Database1 
found that women younger than 26-years-old had substantial increases in early stage cervical 
cancer diagnoses as a result of the dependent coverage mandate (Robbins et al., 2015). When 
examining changes in cervical cancer screening rates utilizing national self-report data from the 
Behavioral Risk Factor Surveillance System (BRFSS)2 and Medical Expenditure Panel Survey 
(MEPS)3, evidence remains mixed for young women (Garrdio et al, 2020; Han et al., 2015; 
Bhandari & Li, 2019). The mixed results in screening utilization may reflect the changes in cervical 
screening guidelines that occurred concurrently with the national implementation of the ACA. 
Additionally, the development and uptake of the HPV vaccine, approved for use in the United 
States in 2006, may impact cervical screening behavior as well (Garrido, 2020). 
 When examining Medicaid expansion, significant expansion effects have been identified 
when considering both cervical cancer screening in low income women (Hendryx, 2018, Sabik et 
al., 2018) and stage at diagnosis (Albright, 2021). Bhandara & Li (2019) also studied outcomes in 
the context of the elimination of cost sharing for preventative services but did not find an increase 
in guideline-concordant utilization among privately insured individuals using MEPS data. A 
supporting study utilizing claims data from Massachusetts found no significant effects on 
                                                 
1 The National Cancer Database is an oncology outcomes database for accredited cancer programs in the United States 
and Puerto Rico, a joint program of the Commission on Cancer of the American College of Surgeons and the American 
Cancer Society  
2 The Behavioral Risk Factor Surveillance System (BRFSS) is a national telephone based health survey that collects 
data on health-related risk behaviors, chronic health conditions and use of preventative services 
3 The Medical Expenditure Panel Survey (MEPS) is a set of surveys of families and individuals, their medical 
providers and employers nationally 
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utilization for cervical cancer screening with elimination of cost sharing for preventative services 
(Steenland et al., 2019).  
Much of the literature has utilized national data from BRFSS or the Surveillance, 
Epidemiology and End Results (SEER) program4. Although these sources provide large, nationally 
representative populations to examine, they lack the granularity that state cancer registries possess 
to examine more specific area level factors and regional changes. Even at the state level, trends 
observed in one state may not extrapolate to another.5 It is important to understand regional trends 
within states to develop targeted and effective cervical cancer prevention and mitigation strategies. 
Moreover, the BRFSS contains self-report data regarding cervical screening practices but does not 
include objective information on cancer stage and treatment. Additional literature has also shown 
that these large population-based databases have underrepresented rural populations (Zahnd et al., 
2019). Based upon 2009–2013 American Community Survey data and the USDA's Rural-Urban 
Continuum Codes (RUCC), only 10.6% of the geography covered in SEER is rural, while 14.8% 
of the U.S. population (more than 46 million people) is rural (Blake et al., 2017). Because the 
research question aims to investigate the impact of the ACA on cervical cancer diagnoses, 
particularly for women living in rural areas of Pennsylvania, the Pennsylvania Cancer Registry 
data is well situated to explore these relationships. To the best of the author’s knowledge, the 
current study will be the first to examine changes in cervical cancer diagnoses in Pennsylvania 
under the context of the Affordable Care Act utilizing Pennsylvania Cancer Registry data. The 
goal of this paper is to investigate the impact of the Affordable Care Act, following Medicaid 
                                                 
4 The Surveillance, Epidemiology and End Results Program (SEER) collects incidence, prevalence and survival data 
on cancer in the United States 
5 For instance, literature has found significant increases in early stage breast cancer diagnoses in Pennsylvania after 
implementation of the ACA (Spada, 2020) while Ohio, a state similar in population and size to Pennsylvania, did not 
exhibit the same trend in breast cancer diagnoses after implementation (Kirkpatrick, 2020) 
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expansion, on cervical cancer diagnoses for women in Pennsylvania, with a focus on minority 
women and rurally located women.  
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2.0 Methods 
2.1 Data and Population 
          This paper utilized data from the Pennsylvania Cancer Registry, a statewide data system 
responsible for collecting information on all new cancer cases diagnosed in Pennsylvania, to 
identify cervical cancer cases in Pennsylvania from 2010 through 2016. The United States 
Preventive Services Task Force recommends cervical cancer screening every three years for 
women aged 21 to 29 years and for women aged 30 to 65 years who screen with cytology (by 
Pap smear) alone. The recommendation of screening every 5 years is for women aged 30 to 65 
years who are screened through cotesting (Pap + hrHPV testing) or through hrHPV testing alone. 
The USPSTF does not recommend screening for women younger than 21 years, older than 65 
years, or for any woman who has had a total hysterectomy. The American Cancer Society has 
suggested that screening can be delayed until age 25 years. Because screening guidelines are 
continuing to shift away from screening younger populations and the assumption that the ACA 
may impact stage at diagnosis through increased access to screening, the sample was limited to 
female residents of Pennsylvania aged 26-64 years of age. Restricting the sample to women aged 
26 years and older also limits biases associated with the implementation of the dependent 
coverage mandate in order to isolate the impact of insurance expansions taking place later than 
2014 in Pennsylvania. Cervical cancer cases diagnosed at death were excluded. The included 




The primary outcome measure was defined as the likelihood that a new case of cervical 
cancer diagnosed (in the county quarter-year) would be categorized as early stage. The National 
Cancer Institute’s SEER summary stage variable is coded within the registry to indicate summary 
stage at the initial diagnosis or treatment of the reportable tumor. Summary stage categorizes how 
far a cancer has spread from its point of origin. The variable uses all information available in the 
medical record; it is a combination of the most precise clinical and pathological documentation of 
the extent of disease. Diagnoses that were in situ, local, or regional by direct extension only were 
considered early-stage; those that were regional with lymph nodes involved, regional not otherwise 
specified, and distant were considered late-stage (Soni et al., 2018, Lin et al., 2020).  
Race and ethnicity were coded according to the SEER Program Coding and Staging 
Manual; codes correspond to racial and ethnic categories used by the U.S. Census Bureau. For 
location of residence subgroups, patients were divided into urban, defined as patients whose census 
tract of residence was assigned a rural–urban commuting area (RUCA) code of 1–3, and nonurban, 
defined as cases with a RUCA code of 4–10 (Cromardie, 2019, Spada et al., 2020). Age at 
diagnosis as recorded in the registry was included in complete years.  
2.3 Statistical analysis 
The effect of Medicaid expansion in Pennsylvania through implementation of the 
Affordable Care Act was assessed on cancer stage at diagnosis using a retrospective natural 
experiment design and interrupted time series analysis. An interrupted time-series analysis is 
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useful for assessing the effects of population-level interventions (i.e. pre- and post-intervention) 
and provides a long term analytical framework that can detect immediate and more delayed 
changes in the outcome of interest (Kontopantelis, 2015). Interrupted time series analysis 
incorporates time and utilizes multiple consecutive pre and post intervention observations in a 
single population. Because the observations are undertaken for the same population, between 
group differences do not present an issue and the temporal structure allows for the control of 
underlying trends and measured time-varying confounders (Bernal et al., 2019).  
In this interrupted time series analysis, the pre-intervention time period is defined as 
January 1st, 2010 through December 31st, 2013. The post intervention period is defined as January 
1st, 2015 through December 31st, 2016. Because health insurance marketplaces under the ACA 
were introduced in 2014, the pre-intervention period will exclude any 2014 observations to limit 
biases associated with the beginning of the implementation of the ACA. Therefore, the resulting 
16 consecutive quarterly time points prior to intervention and eight consecutive quarter periods 
post intervention were examined.6  
Under a single group analysis, the following baseline specification is estimated:  
 
[1] 𝑙𝑜𝑔𝑖𝑡(Pr⁡(𝑌𝑡 = 1)) ⁡= 𝛽0 + 𝛽1𝑇𝑡 + 𝛽2𝑋𝑡 + 𝛽3𝑋𝑡𝑇𝑡 + 𝛽4𝑋𝑖 
 
where Yt is the outcome of interest for early stage diagnoses of cervical cancer measured at each 
quarter year time point, t. The outcome of interest was a binary variable to assess the likelihood 
that a new diagnosis of cervical cancer at the county-quarter level would be categorized as an early 
                                                 
6 Quarters for each year defined as January 1st -March 31st, April 1st –June 30th, July 1st – September 30th and October 
1st – December 31st 
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stage diagnosis.7 Tt is the time since the start of the study in quarter years. Xt is an indicator variable 
representing the implementation of Medicaid expansion in Pennsylvania through the Affordable 
Care Act and XtTt is an interaction term noting the interaction between quarter-year and the 
indicator variable representative of the policy intervention. In the baseline model β0 represents the 
intercept or base level of the likelihood of an early stage cervical cancer diagnoses in the county 
quarter. β1 is the slope or trajectory of early stage cervical cancer diagnoses until the introduction 
of the intervention. β2 represents the change in the level of the outcome that occurs in the period 
immediately following the introduction of the intervention compared with the counterfactual.8 β3 
represents the difference between preintervention and post intervention slopes of the outcome. 
Thus, significant p-values in β2 indicate an immediate treatment effect and significant values in β3 
indicate a treatment effect over time (Linden and Adams, 2011). β4 is represents a vector of 
coefficients for a matrix of covariates of additional individual level characteristics (including age 
at diagnosis, race and rural/urban residence). Multiple logistic regression models utilizing the 
interrupted time series analysis framework were constructed to assess the relationships between 
the implementation of the ACA, patient characteristics and the likelihood of an early stage cervical 
cancer diagnosis. A logistic regression was selected to model relationships of interest because the 
primary outcome examined is measured as the likelihood that a new case of cervical cancer at the 
county-quarter year level is categorized as early stage, which should follow a binomial distribution. 
Standard errors were clustered at the county level. The model does not specify an error term 
because logistic regression models the predicted mean rather than modelling each value of the 
outcome with a predicted mean plus an error term consistent with other types of generalized linear 
                                                 
7 Yt =1 if early stage, Yt = 0 if late stage  
8 The preintervention trend projected into the treatment period serves as the counterfactual in the case of a single group 
model such as this one 
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models (Chang, 2021). Odds ratios with 95% confidence intervals are presented for each logistic 
regression. Statistical significance was assessed at a significance level of .05. 
The assumptions necessary for causal inference in the single-group interrupted time series 
analysis are plausible when the preintervention trend prior to the expansion of Medicaid as a part 
of the ACA is flat or consistent followed by a significant change in the outcome variable 
immediately following expansion that is sustained over time. Assumptions for use of logistic 
regression models with an interrupted time series framework were assessed and conclusions are 
reported in the results section of the paper.  
Stratified models were estimated to assess the impact of Medicaid expansion on early stage 
cervical cancer diagnoses for subpopulations of women in Pennsylvania. The first set of stratified 
models examined the likelihood that a new case of cervical cancer at the county-quarter year level 
would be categorized as early for non-white women in the sample versus minority women. The 
second set of stratified models examined the likelihood that a new case of cervical cancer at the 
county-quarter year level would be categorized as early for women who live in non-urban areas 
(large towns or rural areas) compared to urban areas of the state. All models controlled for age at 
diagnosis. All data management and analysis was completed in Stata (16.1, StataCorp LLC, 
College Station, Texas).  
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3.0 Results 
Sample characteristics by pre and post ACA interruption time periods are shown in Table 
1 below. Sixty-six of Pennsylvania’s 67 counties were included in analysis. Unstaged cases were 
excluded from the analysis population providing a sample of 2,052 total diagnosed cases of 
cervical cancer during the study period. Within this study population, the average age was 46 years 
(SD = 10.24). Most women were white (79.74%) and non-Hispanic (90.99%) and were privately 
insured (52.13%). Interestingly, the percentage of women with Medicaid as their primary source 
of coverage at diagnosis significantly decreased in the post Medicaid expansion period from 
28.89% prior to the implementation of the ACA to 23.99% in the post intervention period (z=4.59, 
p<.001). The number of uninsured women did decrease in the post intervention period, although 
this difference was not statistically significant (z=1.42, p=.16). Sixty five percent of cases of 
cervical cancer were categorized as early stage in both the pre and post ACA periods. Overall, 
there were small imbalances in demographic characteristics between the pre and post ACA 
periods.  
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Table 1. Summary statistics for cervical cancer cases: overall and by time period 
Note: privately insured indicates cases coded with managed care, HMO and PPO plans; American Indian includes 
all indigenous populations of the Western hemisphere; Other Asian includes Asian, NOS, and Oriental, NOS 
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In the full baseline model, the dependent variable measured the likelihood that a new case 
of cervical cancer in the county-quarter year would be categorized as early stage. The full model 
controlled for age, race and location of residence. Table 2 displays results from logistic regression 
models predicting the odds of early stage cancer diagnosis at the county-quarter year over time 
period 2010-2016. The table includes results from the full baseline specification and the stratified 
models examining effects for subpopulations of women in Pennsylvania. 
 
Table 2. Results from logistic regression models predicting the odds of early stage cervical cancer diagnosis 
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 In the full model, there was not a significant treatment effect of ACA implementation (ß3) 
on the likelihood of early stage cervical cancer diagnosis found over time (OR=1.06, CI: 0.98, 
1.14, z=1.52, p=.128). There also was not any significant change in the likelihood of early stage 
diagnosis in the quarterly period immediately following the implementation (ß2) of the ACA 
(OR=0.27, CI: 0.06, 1.17, z=-1.75, p=.08). Although not significant, the negative ß2 coefficient 
suggests the model’s estimate of a sizeable drop in likelihood of early stage cervical cancer 
diagnoses in the period following policy implementation (ß2= -1.31 as compared to ß0 =2.55), a 
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counterintuitive result in the context of a hypothesis arguing that early stage diagnoses were likely 
to increase after the implementation of the ACA in 2015. ß0 represents the baseline odds of early 
stage cervical cancer diagnosis in this population estimated by the model at 10.24 (CI: 5.95, 17.61, 
z=8.41, P<.001). In the full baseline model, age at diagnosis (z=-6.48, p<.001) and race (z=-2.51, 
p<.001) were both significant covariates. For each additional year in age, a woman’s odds of being 
diagnosed with early stage cervical cancer (as compared to a late stage diagnosis) decreased by 
4%. In this sample, being white reduced the chance of early stage diagnosis (as compared to a late 
stage diagnosis) by 18%. The sample was predominantly white so this finding could result from 
noise due to the smaller minority populations. When plotting the results of the full model (Figure 
1), although the trends are not statistically significant, it can be observed that the likelihood of an 
early stage diagnosis has a gradual upward sloping trend in the pre intervention period and an 
upward sloping trend in the post intervention period. Despite the smaller intercept at the policy 
intervention, the upward sloping trend in the post intervention period is consistent with the 
hypothesis that the likelihood of early stage diagnosis increases throughout the post intervention 
period and implies that further research using a larger post intervention time period may find a 
significant upward sloping trend.  
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Figure 1. Probability of early stage cervical cancer diagnosis plotted from the baseline model, 2010-2016 
Note: Model not significant at the .05 level 
 
Similar trends were seen in the stratified models used to estimate impacts for various 
subpopulations of women in Pennsylvania. Because the sample contained small numbers of each 
category of non white race,9 categories were combined together to represent minority women. 
When considering non white women in Pennsylvania, there was not a significant treatment effect 
of ACA implementation over time (OR=1.00, CI: 0.80, 1.26, p=.975) nor was there an immediate 
treatment effect following implementation (OR=1.10, CI: 0.01, 205.51, p=.970). When 
considering only White women, there was not a significant treatment effect of the ACA over time 
(OR=1.06, CI: 0.98, 1.16, p=.135), but there was a marginally significant immediate treatment 
                                                 
9 Black women comprised 14.99% of the total sample while all other categories comprised less than 1% of the total 
sample 
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effect (OR= 0.22, CI: 0.05, 1.02, p=.054). There were no significant treatment effects of the ACA 
over time when considering women living in urban areas (OR: 1.04, CI: 0.96, 1.13, p=.324), 
women living in large towns (OR: 1.09, CI: 0.86, 1.39, p=.466) and women living in rural areas 
(OR: 1.57, CI: 0.88, 2.83, p=.129). In addition, there were no significant immediate treatment 
effects following implementation when considering women living in urban areas (OR: 0.35, CI: 
0.07, 1.73, p=.200), women living in large towns (OR: 0.22, CI: 0.00, 49.51, p=.586) and women 
living in rural areas (OR: <.001, CI: <.001, 3.46, p=.081). Age and race remained significant 
covariates in all stratified models except for the model including only women living in a large 
town in which neither age nor race were significant.  
Finally, post estimation diagnostics were conducted to determine fit of the model and check 
assumptions of the logistic regression used to model relationships between early stage cervical 
cancer diagnosis, implementation of the ACA and patient characteristics over the study period. 
Multiple logistic regression requires that observations are independent, that the outcome of interest 
is a binary variable and that predictors are linearly related to logit of the outcome. The sample did 
not consist of repeated measures or matched data so independence is satisfied. The independent 
variables are linearly related to the logit of the binary outcome for early stage cervical cancer 
diagnoses as depicted in partial residual plots (plots contained in Appendix B).  In addition to the 
odds ratios of predictors in the model, the pseudo r-squared statistic provides a measure of effect 
size for the model. In the full baseline model, the pseudo r-squared is calculated at .0275. 
Generally, a pseudo r-squared of at least .20 indicates that the assessed model provides an 
improvement over the null model (Scott, 2020). In this case, the small pseudo r-squared implies 
that the specified model may not be an ideal fit for the variables included. Variance inflation factor 
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(VIF) was assessed for each independent variable; VIFs remained low indicating that 
multicollinearity is not an issue within the model.10  
Additional model specifications were tested to explore the counterintuitive trends that were 
indicated in the full baseline specification and stratified models. Given that the ACA impacted 
access to care for women in Pennsylvania through Medicaid expansion, a model limited to only 
cases reported with Medicaid as the primary payer at diagnosis was tested. Results were consistent 
with the full baseline model and stratified models: none of the results were estimated as significant 
and the coefficient for ß2 remained negative, indicating a drop in likelihood in early stage cervical 
cancer diagnoses with the implementation of the ACA. A model excluding all patient characteristic 
covariates (age, race and location of residence) was explored as well. Interestingly, results 
remained consistent in this model as well, with very minimal shifts in each of the coefficient 
estimates (and no significant impact of the policy intervention) suggesting that the trends that are 
observed are not largely explained by patient characteristics. The full baseline model was also 
tested using a linear regression because of the issues associated with interpreting odds ratios in 
logistic regression models that contain interaction terms (Karaca-Mandic et al., 2011). Results 
were consistent in the linear regression as well.  
                                                 




The current study examined the impact of Medicaid expansion, implemented through the 
ACA, on early stage diagnoses of cervical cancer for women in Pennsylvania, particularly among 
minority women and those in rural areas of the state. It was hypothesized that with increased access 
to cervical cancer screenings and healthcare through Medicaid expansion as a part of the ACA, the 
likelihood of cervical cancer diagnosis at an early stage would increase for women in 
Pennsylvania. Early stage diagnosis of cervical cancer is associated with increased survival rates 
and overall improved prognosis and quality of life. It was also argued that the implementation of 
the ACA may have larger impacts on cervical cancer outcomes for women living in rural areas of 
the state and minority women of the state, who are less likely to be insured and to be up to date 
with cervical cancer screenings (MacLaughlin et al., 2019). The current study is the first to 
examine changes in cervical cancer diagnoses in Pennsylvania in the context of the Affordable 
Care Act utilizing Pennsylvania Cancer Registry data. However, this study did not find a 
significant effect of ACA implementation on early stage cervical cancer diagnoses across 
Pennsylvania, both when examining the full model and when stratifying to examine effects for 
specific subpopulations, but does highlight interesting trends in patterns of diagnosis between 2010 
and 2016 and motivates further research into each of these trends.  
When considering all cases of cervical cancer diagnosed during the study period, there was 
not a significant treatment effect of ACA implementation on the likelihood of early stage cervical 
cancer diagnosis found over time. There also was not any significant change in the likelihood of 
early stage diagnosis in the quarterly period immediately following the implementation of the 
ACA. These results were consistent when considering subpopulations of women, including non 
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white women and women who reside in non-urban areas. Age and race were estimated as 
significant covariates in the majority of models. Although not statistically significant, the full 
model estimated a sharp drop in the likelihood of early stage diagnoses at policy implementation 
followed by an upward sloping trend in the post intervention period. These results are contrary to 
the hypothesis and are inconsistent with some previous literature. 
Previous literature has found significant reductions in the rate of uninsurance at diagnosis 
for women with cervical cancer nationally (Zhao, 2020; Albright, 2021). The current study did not 
find a significant decrease in the number of cases diagnosed without coverage, although the 
numbers of cases diagnosed without insurance were very small (n=47) potentially contributing to 
the lack of significance observed. Additionally, the number of cases diagnosed with Medicaid as 
the primary source of coverage significantly decreased over the study period, the opposite result 
of what was expected with the expansion of Medicaid in 2015. Nationally, enrollment in Medicaid 
increased quickly after expansions as a part of the ACA (Berchick et al., 2019). There were also 
smaller increases in enrollment in non expansion states, likely due to the “welcome mat effect,” in 
which enrollment increases among individuals who were previously eligible for coverage but not 
enrolled. The majority of literature has not has described significant decreases in Medicaid 
enrollment immediately following the ACA in expansion states such as Pennsylvania (Kaiser 
Family Foundation, 2019), as was found in the current study. Beginning in 2017, diverse groups 
of states, including Wyoming, Missouri and New Hampshire, saw decreases in Medicaid 
enrollment (MACPAC, 2019) due to a number of factors.11 The proportion of cases diagnosed 
with Medicaid as primary coverage was moderate in the sample (almost one third of the sample) 
                                                 
11 Kaiser Family Foundation (2019) reports that changing economies, renewal process barriers, and a reduction of 
funds in outreach and enrollment assistance may all play a role in the decreases in enrollment observed across a 
number of states.  
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likely ruling out noisy data as an explanation for this finding. The result motivates questions 
regarding the effectiveness of the policy implementation in Pennsylvania, for example, were 
women who were eligible to enroll in Medicaid able to enroll in 2015? Was there sufficient 
promotion of the policy change in the first year of implementation? Did patients have the necessary 
tools to complete paperwork and apply for enrollment (for example, was the enrollment process 
internet based and also accessible to any Pennsylvania residents who may not have consistent 
internet access)? Reducing barriers to enrollment in Medicaid may be critical to finding a 
significant increase in proportion of patients using Medicaid as their primary coverage source if 
there is one. Moreover, the BCCPTA allows for private insurance coverage at higher income levels 
contingent on a cancer diagnosis so there may have been more women in the 133-200% FPL range 
who utilized private coverage rather than Medicaid post ACA. Additionally, insurance “churning,” 
or coverage disruption or loss, could also explain a significant decrease in enrollment even during 
an expansion period. Difficulties navigating state renewal and redetermination procedures as well 
as income fluctuations or changing family circumstances can result in loss of coverage. Human 
service organizations play a role in this context in helping to get women who may be eligible for 
Medicaid enrolled in post expansion periods.  
Previous studies examining screening utilization also found significant expansion effects 
for cervical cancer screening, although much of the literature has focused on a national scale and 
utilized self-reported survey data (Hendryx et al., 2018; Sabik et al., 2018). Significant expansion 
effects on screening utilization would presumably result in greater early detection of cervical 
cancer thus resulting in greater proportions of early stage cervical cancer diagnoses. Significant 
increases in the proportion of early stage cervical cancer diagnoses for women younger than 26 
years were found as an effect of the implementation of the dependent coverage mandate under the 
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ACA. However, early stage diagnosis trends remained flat for women in the older age group 
studied (Robbins, 2015), similar to the trends observed in the current study despite the statistical 
insignificance. Albright et al. (2021) did find a significant increase in the proportion of early stage 
diagnoses with the implementation of Medicaid expansions, although the analysis was conducted 
at the national level (comparing expansion states to non-expansion states) and aggregated 
gynecological cancers together12 so specific expansion effects for cervical cancer alone are 
unclear. Despite previous evidence that has linked rural residence to differences in cancer 
screening and diagnosis (Paskett et al., 2020), area of residence was not a significant factor in 
explanation of early stage cervical cancer diagnosis in the current study, although the results may 
be biased by the lack of cases in non-urban residential categories.  
The current analysis is potentially limited by unobserved confounders, such as national 
trends in cervical cancer screening and diagnosis. With guidelines shifting towards less frequent 
screening and the increase in the uptake of the HPV vaccine, women may be less likely to be up 
to date with screenings. As of 2019, just over two thirds of women were up to date with cervical 
cancer screenings; this rate can be even lower for certain subpopulations of women (for example, 
those living below the poverty line and those with an education level equivalent to less than a high 
school education) (National Cancer Institute, 2021). Parekh et al. (2017) found a significant 
decrease in guideline-based cervical cancer screening after the change in screening guidelines in 
2009 when examining Pennsylvania Medicaid claims data. Additionally, the American Cancer 
Society adjusted their guidelines for cervical cancer screening in 2012. Although the U.S. 
Preventive Services Taskforce guidelines are considered the standard for clinical 
                                                 
12 Invasive cancers of the uterus, ovary, fallopian tube, cervix, vagina and vulva were aggregated together (Albright 
et al., 2021) 
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recommendations, the shift in recommendations by the American Cancer Society in 2012, in the 
middle of the study period, may have influenced results as well. Infrequent screening of cervical 
cancer increases the likelihood that a case may go undetected for an extended period thus 
increasing the likelihood of diagnosis at a more advanced stage. Potential reasons for infrequent 
screening include a lack of knowledge about guidelines for screening by healthcare providers, 
which may be especially prevalent with continually shifting guidelines and differing guidelines 
between advisory bodies, limited access to healthcare systems and patient expectations. For 
example, women who have received the HPV vaccine may believe that they are exempt from 
regular screening but it is important that women who are vaccinated continue to be screened, 
especially because the vaccine may not protect against all types of cervical cancer (CDC, 2016). 
When considering these trends, it is possible that the cases included in the present study are already 
more likely to be diagnosed at a more advanced stage. Some studies have examined the impact of 
shifting guidelines on utilization of screenings and outcomes that tend to be coupled with cervical 
cancer screening, such as STD testing (Naimer, 2017), but few have specifically investigated the 
impact of recently shifted guidelines directly on early stage diagnoses. Inclusion of national 
immunization and screening rates, from sources such as the National Immunization Surveys or the 
BRFSS, may be helpful additions to models estimating early stage cervical cancer diagnoses.  
The current analysis included covariates for age, race and urban and non-urban residence 
but did not include other patient level or area and system level characteristics. Income level, health 
literacy and health system factors, such as provider concentration and location, have been shown 
to influence cervical cancer outcomes (Moss et al., 2017). Given that the current model estimates 
were not shown to be an improvement over the null hypothesis and remained consistent when 
removing patient characteristics from the model in exploratory analysis, consideration of these 
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systemic and sociodemographic variables will be crucial for future analyses. For example, the 
Appalachian region in particular experiences severe provider shortages. There are 12 percent fewer 
primary care physicians per 100,000 residents and 28 percent fewer specialty physicians per 
100,000 residents in the Appalachian region as compared to the nation overall (Paskett, 2020). The 
severe lack of providers in the region presents further barriers to access even for insured women. 
The current study’s results may also suggest that health promotion factors may be particularly 
important to reducing barriers to cervical cancer prevention in addition to policy interventions such 
as the ACA aimed at reducing financial and coverage barriers. A recent systematic review by 
Kriubarajan (2021) highlights facilitators and barriers to cervical cancer. Facilitators included 
strong self-efficacy in health, a positive and consistent relationship with a healthcare provider and 
health literacy regarding cancer prevention and cervical cancer risk factors. Barriers included 
poorer health literacy, transportation challenges and negative experiences or perceptions of 
gynecological care13 among others. Multilevel public health and health promotion interventions 
will be needed to address cervical cancer health literacy and to incentivize guideline concordant 
screening, particularly for marginalized populations of women.  
The large sample size representative of all counties across the state of Pennsylvania 
remains a strength of the present study. Additionally, restricting the sample to women aged 26 to 
64 years limits any biases associated with the implementation of the dependent coverage mandate 
within the ACA. Use of the Pennsylvania state cancer registry allows for exploration of regional 
trends and provides a more representative presentation of rural communities in the state as 
compared to larger national and state-based surveys. The objective nature of the state cancer 
                                                 
13 History of childhood abuse and sexual trauma increased the risk for cervical cancer through a number of pathways 
including lack of screening, risky sexual behavior and higher levels of smoking and perceived stress (Hindin, 2019) 
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registry ensures that data is reliable and meets quality standards14 as compared to subjective self-
report surveys. Despite these advantages, significant causal relationships could not be inferred 
from this analysis. Although the Pennsylvania Cancer Registry data utilized in this analysis has 
been helpful in exploring regional trends and variations, generalizability is limited because the 
data comes from only one state. Additionally, minority patients in this study were predominantly 
Black whereas the broader nation’s racial and ethnic population is much more diverse. The study 
may be limited by the sole inclusion of a binary outcome to represent likelihood of early stage 
diagnosis of cervical cancer as compared to rates of incidence or counts of cases placed in the 
context of population size. Future studies may look to incorporate these various measures of the 
outcome to capture a more comprehensive perspective on cervical cancer diagnosis in 
Pennsylvania. The current study only has two years of post-intervention data, after the 
implementation of Medicaid expansion in Pennsylvania in 2015, and so may underestimate the 
impact of expansion and access on cervical cancer diagnoses and outcomes for women in 
Pennsylvania. Further research in broader populations with expanded post intervention data and 
more comprehensive models incorporating community level covariates will be needed to provide 
support for true null findings. In conclusion, while the current study did not provide significant 
evidence of the ACA’s impact on early stage diagnoses for Pennsylvania women aged 26 to 64 
years, it does motivate further research to understand the trends observed and additional factors 
that may contribute to cervical cancer prevention for women in Pennsylvania.  
                                                 
14 Reporting to the PCR is mandated by the Pennsylvania Cancer Control, Prevention, and Research Act of 1980 and 
the Pennsylvania Department of Health's regulations concerning Reporting of Communicable and Noncommunicable 
Diseases. Cancer data are reported by hospitals, clinics, laboratories, radiation facilities, cancer centers, surgical 
centers, doctor's offices, death certificates and through data exchange when Pennsylvania residents are diagnosed or 
treated in other states 
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5.0 Public Health Impact 
Cervical cancer is unique in that the vast majority of cases can be prevented through 
screening and vaccination. Detection of cervical cancer at early stages is a key public health 
priority in the United States and has the potential to reduce mortality and disease burden. While 
the present study did not find significant changes in early stage diagnoses of cervical cancer with 
the implementation of the Affordable Care Act in Pennsylvania, it does suggest the crucial roles 
that health promotion and education play in addressing cervical cancer and reducing health 
disparities in cancer control.  
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Appendix A PSite Codes 
The cases included in analysis were restricted to cervix uteri PSite codes: ICD-0-2 Site = 
C530-C539; excluding histology codes 9050-9055, 9140, 9590-9992 
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Appendix B Partial Residual Plots 
 
Appendix Figure 1. Partial residual plot depicting the relationship between the logit and quarter year 
 
Appendix Figure 2. Partial residual plot depicting relationship between the logit and age at diagnosis 
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